Pnc Financial Services Group, Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

Pnc Financial Services Group, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$38.96 - $42.75 $155 - $171	4 Added 33.33%	16 $0
Q1 2024 May 10, 2024	SELL	$40.88 - $43.27 $265,229 - $280,735	-6,488 Reduced 99.82%	12 $0
Q4 2023 Feb 09, 2024	SELL	$20.27 - $42.44 $60,931 - $127,574	-3,006 Reduced 31.62%	6,500 $275,000
Q3 2023 Nov 13, 2023	BUY	$20.26 - $31.91 $78,325 - $123,364	3,866 Added 68.55%	9,506 $207,000
Q2 2023 Aug 11, 2023	BUY	$23.9 - $35.38 $134,796 - $199,543	5,640 New	5,640 $179,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.